Evidence map›Paper›PMID 40102272›Full record

ReviewVirchows Archiv : an international journal of pathology2025

Unique clinical, morphological, and molecular characteristics of tumors associated with PSC-IBD.

Andrea Vajsova, Monika Cahova, Lukas Bajer, Eva Sticova, Ivana Juskova, Mojmir Hlavaty, Ondrej Fabian

Abstract readReview
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrea VajsovaClinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic. andrea.vajsova@vfn.cz.ORCID http://orcid.org/0000-0002-8473-8664
Monika CahovaExperimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic.
Lukas BajerDepartment of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, 14021 , Czech Republic.
Eva SticovaClinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic.
Ivana JuskovaClinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic.
Mojmir HlavatyDepartment of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, 14021 , Czech Republic.
Ondrej FabianClinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease characterized by chronic inflammation and progressive fibrosis of the biliary tree, leading to significant liver function impairment over time. There is a strong association with inflammatory bowel diseases (IBD), together representing a distinct and complex medical condition. Patients with PSC-IBD face a heightened risk of various cancers, particularly colorectal carcinoma (CRC) and cholangiocarcinoma (CCA) as the most common types. In this review, we aim to characterize the distinctive features of PSC-IBD-associated carcinomas. Cancer pathogenesis in PSC-IBD is shaped by various factors including dysregulated bile acid metabolism, gut dysbiosis, and unique immune responses. PSC-IBD-associated CRC is often right-sided and warrants vigilant monitoring due to its higher incidence and unique morphological features compared to CRC arising in the terrain of IBD alone. CCA shares substantial genetic similarities with extrahepatic CCA and poses diagnostic challenges since it is frequently detected at advanced stages due to symptom overlap with PSC. Besides, reliable predictive biomarkers for targeted therapy remain largely unexplored. The distinct molecular, genetic, and histopathological profiles of CRC and CCA in PSC-IBD underscore the complexity of these malignancies and highlight the need for continued research to develop precise therapeutic strategies.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaCholangitis, SclerosingColorectal NeoplasmsInflammatory Bowel DiseasesBiomarkers, TumorHumansBiomarkers, TumorCholangiocarcinomaColorectal carcinomaCrohn’s diseaseInflammatory bowel diseasePrimary sclerosing cholangitisUlcerative colitis

Identifiers

PMID40102272
PMCPMC12018527

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.